Work

Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice

Year: 2004

Type: article

Source: Neurobiology of Disease

DOI: 10.1016/j.nbd.2004.07.011

Authors: Fran Norflus, Agnes Nanje, Claire-Anne Gutekunst, Geming Shi, Joshua Cohen, Michelle Bejarano, Jonathan Fox, Robert J. Ferrante, Steven M. Hersch

Institutions: Massachusetts General Hospital, Emory University, Boston University, Edith Nourse Rogers Memorial Veterans Hospital, Harvard University

Language: English

Topic: Genetic Neurodegenerative Diseases

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Center for Complementary and Integrative Health

Awards: G1064289161, G1856555311, Combination Drug Therapy in Huntington's Disease, G1964600565, G2466425206, G2530945350, Transcription and Therapy for HD: from Molecules to Man, G3460930458, HUNTINGTON PROTEIN AND THE HUNTINGTON'S DISEASE MUTATION, Boston University Alzheimer's Disease Center, OXIDATIVE AND EXCITATORY TOXICITY IN NEURODEGENERATION

OpenAlex ID: W2018178356

FWCI: 0.469

Cites: 38

Cited by: 42

Related to: 10